ストックスクリーナーアプリを入手
146.38
0.58%
0.85
アフターアワーズ：
146.00
-0.38
-0.26%
Neurocrine Biosciences Inc (NBIX) 最新ニュース
Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuation - ChartMill
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? - Zacks Investment Research
Healthcare stocks with strong revenue growth and attractive valuations - TradingView
Neurocrine's 23% Slide Puts Ingrezza Raise And Crenessity Ramp Under The Microscope - Finviz
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia - PR Newswire
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? - Zacks Investment Research
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Where Will Neurocrine Biosciences Be in 5 Years? - Yahoo Finance
Where Will Neurocrine Biosciences Be in 5 Years? - The Motley Fool
Neurocrine Biosciences, Inc. Estimates – NASDAQ:NBIX - TradingView
Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome - PR Newswire
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance UK
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance
Neurocrine Biosciences Inc (NBIX) Stock Up 3.7% and Still Underv - GuruFocus
Neurocrine Biosciences starts Alzheimer's Phase 2 trial - Mugglehead Investment Magazine
Neurocrine Biosciences Initiates Phase 2 Study of Investigational Compound to Treat Alzheimer's Disease - Yahoo Finance
Neurocrine Biosciences starts Phase 2 trial of NBI-1117567 for mild to moderate Alzheimer's cognitive impairment - Pluang
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease - TradingView
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease - PR Newswire
Wedbush Cuts Price Target on Neurocrine Biosciences to $186 From $194, Keeps Outperform Rating - Yahoo Finance
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance Australia
How New CRENESSITY Data At Neurocrine Biosciences Stock Has Changed Its Investment Story - Simply Wall Street
How New CRENESSITY Data At Neurocrine Biosciences Stock Has Changed Its Investment Story - Simply Wall Street
Neurocrine Biosciences (NBIX) Stock Trades Below Fair Value On Earnings - Yahoo Finance
Is Neurocrine Biosciences (NBIX) Undervalued On Pipeline And Pricing Risks? - Simply Wall Street
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia - PR Newswire
Needham reiterates Buy rating on Neurocrine Biosciences, $204 price target - TradingView
RBC keeps USD 187.00 target for Neurocrine Biosciences stock - ad-hoc-news.de
JPMorgan reports a passive stake in Neurocrine Biosciences (NBIX) - Stock Titan
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance Canada
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance
Non-operating income (total) of Neurocrine Biosciences, Inc. – HAN:NB3 - TradingView
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance UK
TD Cowen reiterates Neurocrine Bio stock rating on growth outlook - Investing.com
TD Cowen reiterates Neurocrine Bio stock rating on growth outlook By Investing.com - Investing.com India
Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term - Zacks Investment Research
This Biopharma Stock Offers Compelling Upside After a Pullback - Barron's
Is Neurocrine Biosciences Inc (NBIX) a Bargain After 4.4% Drop? GF Value Says Undervalued - GuruFocus
Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - Yahoo Finance Singapore
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For? - Yahoo Finance
Neurocrine Biosciences' Vykat XR Sales Likely to Remain 'Flattish' Near Term, RBC Says - Yahoo Finance
NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now? - Zacks Investment Research
Enterprise value to revenue forward of Neurocrine Biosciences, Inc. – FWB:NB3 - TradingView
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term - Zacks Investment Research
BMO Capital Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Cuts Target Price to $150 - Moomoo
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results - Porterville Recorder
Neurocrine is set to release Q3 results at 1 p.m. Pacific on Nov. 2, then host a call. - Stock Titan
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results - Yahoo Finance
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results - Arizona Daily Star
0.28%
2.60%
大文字化:
|
ボリューム (24 時間):